Tempus AI, Inc. (NASDAQ:TEM) COO Sells $234,803.16 in Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 2,868 shares of the business’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $81.87, for a total value of $234,803.16. Following the sale, the chief operating officer now owns 944,460 shares in the company, valued at $77,322,940.20. This represents a 0.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $62.50, for a total value of $1,250,000.00.
• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $39.61, for a total value of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total value of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00.

Tempus AI Price Performance

Tempus AI stock opened at $68.09 on Friday. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The business has a fifty day moving average price of $50.29 and a 200-day moving average price of $51.72. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Kovitz Investment Group Partners LLC purchased a new position in Tempus AI during the 3rd quarter valued at about $1,367,000. China Universal Asset Management Co. Ltd. bought a new stake in Tempus AI during the 4th quarter valued at approximately $1,091,000. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $178,000. Finally, Captrust Financial Advisors bought a new stake in shares of Tempus AI in the 3rd quarter worth approximately $2,726,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on TEM. Wolfe Research began coverage on Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Loop Capital reduced their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. TD Cowen reaffirmed a “buy” rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a report on Tuesday, January 14th. Finally, Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.